歌礼制药-B(01672.HK)变更部份所得款项用途
歌礼制药-B(01672.HK)公布,变更余下所得款项净额的用途。其中,将用於公司管线产品持续研发的所得款项净额的总比例已由约65%上调至约75%,主要用於将研发组合扩展至两个新疾病领域:乙型肝炎临床治癒及NASH;因公司与Medivir AB终止合作,因此停止原订用於ASC21的研发开支;因应於2020年全口服治疗方案已成为丙肝治疗标准,许多丙肝病人不再选择戈诺卫(达诺瑞韦)加注射干扰素的治疗方案,故下调此部份的款项额度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.